Edition:
India

Clementia Pharmaceuticals Inc (CMTA.OQ)

CMTA.OQ on NASDAQ Stock Exchange Global Select Market

14.06USD
15 Jun 2018
Change (% chg)

-- (--)
Prev Close
$14.06
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,365
52-wk High
$20.12
52-wk Low
$11.77

Latest Key Developments (Source: Significant Developments)

Clementia's Treatment With Palovarotene Significantly Reduces New Bone Growth In Patients With FOP
Wednesday, 23 May 2018 

May 23 (Reuters) - Clementia Pharmaceuticals Inc ::CLEMENTIA REPORTS POSITIVE PHASE 2 PART B DATA SHOWING TREATMENT WITH PALOVAROTENE SIGNIFICANTLY REDUCES NEW BONE GROWTH IN PATIENTS WITH FOP.PHASE 2 PART B DATA SHOW EVALUABLE PATIENTS WITH NO NEW BONE AT 12 WEEKS HAD NO NEW BONE AT 12 MONTHS.STATISTICALLY SIGNIFICANT 91% REDUCTION OF NEW HO AT FLARE-UP SITES AT 12 WEEKS; 65% REDUCTION OF NEW HO AT 12-MONTH WBCT SCAN IN PHASE 2 DATA.PALOVAROTENE GENERALLY WELL-TOLERATED IN TRIAL, CONSISTENT WITH EXPERIENCE ACROSS PALOVAROTENE CLINICAL STUDIES.RECENTLY SURPASSED ENROLLMENT OF FIRST 35 PATIENTS IN OUR PHASE 3 MOVE TRIAL, ON TRACK TO COMPLETE STUDY ENROLLMENT BY YEAR END.ON TRACK TO REPORT FIRST INTERIM ANALYSIS FOR MOVE TRIAL IN MID-2019.  Full Article

Clementia Initiates Pivotal Phase 3 MOVE Trial For Palovarotene
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Clementia Pharmaceuticals Inc ::CLEMENTIA INITIATES PIVOTAL PHASE 3 MOVE TRIAL FOR PALOVAROTENE IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA.CLEMENTIA PHARMACEUTICALS INC - COMPLETION OF ENROLLMENT FOR PHASE 3 MOVE TRIAL EXPECTED BY END OF 2018.  Full Article

Clementia Pharmaceuticals qtrly loss per share ‍$1.83​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Clementia Pharmaceuticals Inc ::Clementia Pharmaceuticals Inc - qtrly loss per share ‍$1.83​.Clementia Pharmaceuticals Inc- ‍as of September 30, 2017, had cash and investments of $152.2 million​.Clementia - ‍anticipates reporting preliminary results from part b open-label extension portion of phase ii study of palovarotene in fop in Q2 2018​.Clementia Pharmaceuticals Inc- on track to begin move study protocol phase iii study and enroll first patient by end of 2017​.  Full Article

BRIEF-Clementia Pharmaceuticals Inc Q4 2017 Loss Per Share $0.37

* Q4 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage: